IL131021A0 - Multiple site delivery of adenoviral vector for the induction of angiogenesis - Google Patents

Multiple site delivery of adenoviral vector for the induction of angiogenesis

Info

Publication number
IL131021A0
IL131021A0 IL13102198A IL13102198A IL131021A0 IL 131021 A0 IL131021 A0 IL 131021A0 IL 13102198 A IL13102198 A IL 13102198A IL 13102198 A IL13102198 A IL 13102198A IL 131021 A0 IL131021 A0 IL 131021A0
Authority
IL
Israel
Prior art keywords
target tissue
angiogenesis
adenoviral vector
blood vessel
vessel formation
Prior art date
Application number
IL13102198A
Other languages
English (en)
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/801,352 external-priority patent/US5846225A/en
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Publication of IL131021A0 publication Critical patent/IL131021A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)
IL13102198A 1997-01-29 1998-01-29 Multiple site delivery of adenoviral vector for the induction of angiogenesis IL131021A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3660197P 1997-01-29 1997-01-29
US08/801,352 US5846225A (en) 1997-02-19 1997-02-19 Gene transfer therapy delivery device and method
US7115698P 1998-01-13 1998-01-13
PCT/US1998/001638 WO1998032859A1 (en) 1997-01-29 1998-01-29 Multiple site delivery of adenoviral vector for the induction of angiogenesis

Publications (1)

Publication Number Publication Date
IL131021A0 true IL131021A0 (en) 2001-01-28

Family

ID=27365066

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13102198A IL131021A0 (en) 1997-01-29 1998-01-29 Multiple site delivery of adenoviral vector for the induction of angiogenesis

Country Status (16)

Country Link
US (2) US6518255B2 (enExample)
EP (1) EP1012291B1 (enExample)
JP (1) JP2001509168A (enExample)
KR (1) KR20000070572A (enExample)
AT (1) ATE279518T1 (enExample)
AU (1) AU745409B2 (enExample)
BR (1) BR9806819A (enExample)
CA (1) CA2278621A1 (enExample)
DE (1) DE69827021T2 (enExample)
HU (1) HUP0001964A3 (enExample)
IL (1) IL131021A0 (enExample)
MX (1) MXPA99006993A (enExample)
NO (1) NO993669L (enExample)
NZ (1) NZ336838A (enExample)
PL (1) PL334902A1 (enExample)
WO (1) WO1998032859A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238673B2 (en) 1989-03-31 2007-07-03 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
BR9806819A (pt) * 1997-01-29 2000-05-09 Cornell Res Foundation Inc Fornecimento de múltiplos locais de vetor adenoviral para a indução de angiogênese.
US6775574B1 (en) * 1997-11-07 2004-08-10 Medtronic, Inc. Method and system for myocardial infarction repair
US6458092B1 (en) 1998-09-30 2002-10-01 C. R. Bard, Inc. Vascular inducing implants
US6251079B1 (en) 1998-09-30 2001-06-26 C. R. Bard, Inc. Transthoracic drug delivery device
WO2000024415A2 (en) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
AU5646300A (en) * 1999-02-10 2000-08-29 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of stimulating angiogenesis
US6986784B1 (en) 1999-05-14 2006-01-17 C. R. Bard, Inc. Implant anchor systems
US6440945B1 (en) * 1999-05-27 2002-08-27 Instituto Dermopatico Dell'immacolata Method of inducing angiogenesis in nonis chemic skeletal muscle
AU5624400A (en) * 1999-06-18 2001-01-09 Collaborative Group, Ltd., The Hyaluronic acid film and matrix for sustained gene transfer
EP1067190A1 (en) * 1999-07-09 2001-01-10 Introgene B.V. Gene therapy for enhancing and/or inducing angiogenesis
US6855160B1 (en) 1999-08-04 2005-02-15 C. R. Bard, Inc. Implant and agent delivery device
EP1199992A1 (en) 1999-08-05 2002-05-02 Cornell Research Foundation, Inc. Gene therapy platformed needle and method of administering a therapeutic solution to a heart
FR2799465B1 (fr) * 1999-10-12 2004-02-13 Centre Nat Rech Scient Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
HK1048593A1 (zh) * 1999-11-05 2003-04-11 The Regents Of The University Of California 用於通过体内基因输送治疗心血管疾病的技术和组合物
US6329348B1 (en) * 1999-11-08 2001-12-11 Cornell Research Foundation, Inc. Method of inducing angiogenesis
US7232421B1 (en) 2000-05-12 2007-06-19 C. R. Bard, Inc. Agent delivery systems
US6508802B1 (en) 2000-05-23 2003-01-21 Cornell Research Foundation, Inc. Remote sensing gene therapy delivery device and method of administering a therapeutic solution to a heart
US7204847B1 (en) 2000-07-28 2007-04-17 C. R. Bard, Inc. Implant anchor systems
US6939540B1 (en) 2000-07-31 2005-09-06 Cornell Research Foundation, Inc. Method of enhancing bone density
KR20020059609A (ko) * 2000-08-04 2002-07-13 벤슨 로버트 에이치. 혈관 내피 성장 인자 ２
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
US6793918B2 (en) * 2000-11-01 2004-09-21 Ludwig Institute For Cancer Research In vivo stimulation of angiogenic activity
JP2005501802A (ja) * 2001-01-23 2005-01-20 ボストン　サイエンティフィック　コーポレイション 虚血心筋を処置するための限局性心筋注入方法
AR027161A1 (es) * 2001-05-15 2003-03-19 Bio Sidus S A Metodo para inducir la proliferacion neovascular y regeneracion tisular
CA2406687A1 (en) * 2001-11-09 2003-05-09 Transgene S.A. Chimeric promoters for controlling expression in muscle cells
AU2003291526A1 (en) * 2002-11-15 2004-06-15 Genvec, Inc Coronary artery disease treatment
KR100912994B1 (ko) 2004-04-05 2009-08-21 더 리전트 오브 더 유니버시티 오브 캘리포니아 Ｎｋｇ２ｄ의 조절
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
RU2321631C2 (ru) * 2005-06-24 2008-04-10 Государственное учреждение Российский научный центр хирургии РАМН Неинфекционный для человека аденовирус как вектор для заместительной генной терапии нарушений ангиогенеза, обеспечивающий эффективный синтез ангиогенина человека в трансфецированных клетках млекопитающих, способ индукции ангиогенеза, способ лечения ишемической болезни, композиция для индукции ангиогенеза и лечения ишемической болезни
US7751883B2 (en) 2006-04-25 2010-07-06 Eugenio Picano System and method for promoting coronary angiogenesis
US9598673B2 (en) * 2006-05-19 2017-03-21 Creative Medical Health Treatment of disc degenerative disease
US8983570B2 (en) * 2007-03-27 2015-03-17 Cardiovascular Biotherapeutics, Inc. Therapeutic angiogenesis for treatment of the spine
US11224635B2 (en) 2007-03-27 2022-01-18 Venturis Thereuptics, Inc. Therapeutic angiogenesis for treatment of the spine and other tissues
CA2703263C (en) 2007-11-01 2014-03-18 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
US8088108B2 (en) * 2009-08-22 2012-01-03 Joseph Wayne Kraft Rapid local anesthesia injection cone
US8409147B2 (en) * 2009-08-22 2013-04-02 Joseph Wayne Kraft Rapid local anesthesia linear injection device
CA2772610C (en) 2009-08-28 2018-01-23 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
WO2014036222A1 (en) * 2012-08-30 2014-03-06 Emory University Systems, methods and computer readable storage media storing instructions for integrating fluoroscopy venogram and myocardial images
PT2945642T (pt) * 2013-01-17 2024-05-27 Medizinische Hochschule Hannover Proteína do fator 1 para utilização no tratamento ou prevenção de doenças
WO2016134293A1 (en) 2015-02-20 2016-08-25 Baylor College Of Medicine p63 INACTIVATION FOR THE TREATMENT OF HEART FAILURE
ES3057136T3 (en) 2016-12-05 2026-02-26 Nuritas Ltd Compositions comprising peptide wkdeagkplvk
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
EP4041192A4 (en) * 2019-10-09 2023-11-08 Xylocor Therapeutics, Inc. EPICARDIAL GENE THERAPY DELIVERY
WO2024233783A1 (en) 2023-05-09 2024-11-14 Cornell University Expression cassette coding for vascular endothelial growth factor

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US510413A (en) 1893-12-12 Drainage-tube
US2551902A (en) 1948-09-10 1951-05-08 Arthur Schaffer Dehorning fluid ejector
US2670673A (en) 1950-07-17 1954-03-02 Joyce A Gordon Fluid injecting device
US3467096A (en) 1966-04-12 1969-09-16 Ferrell S Horn Multiple hypodermic syringe arrangement
FR1584474A (enExample) 1968-02-20 1969-12-26
US3572336A (en) 1968-04-30 1971-03-23 Daniel R Hershberg Syringe
US4150669A (en) 1977-03-16 1979-04-24 Alvaro Latorre Apparatus for effecting and enhancing an erection
US4167179A (en) 1977-10-17 1979-09-11 Mark Kirsch Planar radioactive seed implanter
US5335670A (en) 1986-04-18 1994-08-09 Henry Fishman Allergy testing method and apparatus
JPS6438100A (en) 1987-07-31 1989-02-08 Toray Industries Vascular endothelial cell growth factor
JPH02117698A (ja) 1988-10-27 1990-05-02 Toray Ind Inc 血管内皮細胞成長因子
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
JPH02279698A (ja) 1989-04-20 1990-11-15 M K Medical:Kk 血管内皮細胞成長因子及びその製造方法
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
CA2017379C (en) 1989-05-24 2002-06-25 Kenneth A. Thomas, Jr. Purification and characterization of a glioma-derived growth factor
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
JPH03178996A (ja) 1989-12-06 1991-08-02 Makoto Goto 成長因子
US6228844B1 (en) * 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
DE69132040T2 (de) 1990-09-21 2000-11-02 Merck & Co., Inc. Wachstumsfaktor II für vaskuläre Endothelzellen
DE69229454T2 (de) 1991-03-28 2000-01-05 Merck & Co., Inc. Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors
US5244460A (en) 1991-11-27 1993-09-14 The United States Of America As Represented By The Department Of Health And Human Services Method to foster myocardial blood vessel growth and improve blood flow to the heart
EP0550296A3 (en) 1991-11-28 1993-12-29 Terumo Corp Vascular endothelial cells growth factor
US5290258A (en) 1992-07-27 1994-03-01 Genesis Industries, Inc. Syringe for administering sequentially multiple doses of a medicament
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
DK0751992T3 (da) 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5417683A (en) 1994-07-13 1995-05-23 Shiao; I-Shen Mini-graft hair implanting device for implanting multiple clumps of hair follicles at one time
JPH10507758A (ja) * 1994-10-19 1998-07-28 ジェネティック セラピー，インコーポレイテッド アデノウイルスおよび免疫抑制剤同時反復投与を伴う遺伝子治療
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
JP3178996B2 (ja) 1995-08-24 2001-06-25 沖電気工業株式会社 カード処理装置及びカード送り速度の制御方法
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US5846225A (en) 1997-02-19 1998-12-08 Cornell Research Foundation, Inc. Gene transfer therapy delivery device and method
BR9806819A (pt) * 1997-01-29 2000-05-09 Cornell Res Foundation Inc Fornecimento de múltiplos locais de vetor adenoviral para a indução de angiogênese.
JP3371331B2 (ja) * 1998-12-14 2003-01-27 セイコーエプソン株式会社 インクジェット式記録ヘッドおよびその製造方法

Also Published As

Publication number Publication date
NZ336838A (en) 2002-04-26
EP1012291A1 (en) 2000-06-28
AU6253098A (en) 1998-08-18
BR9806819A (pt) 2000-05-09
NO993669D0 (no) 1999-07-28
KR20000070572A (ko) 2000-11-25
DE69827021T2 (de) 2005-02-24
HUP0001964A2 (hu) 2000-10-28
DE69827021D1 (de) 2004-11-18
EP1012291B1 (en) 2004-10-13
AU745409B2 (en) 2002-03-21
NO993669L (no) 1999-09-27
JP2001509168A (ja) 2001-07-10
US20030103943A1 (en) 2003-06-05
WO1998032859A1 (en) 1998-07-30
MXPA99006993A (es) 2005-06-01
ATE279518T1 (de) 2004-10-15
US20010041679A1 (en) 2001-11-15
US6518255B2 (en) 2003-02-11
PL334902A1 (en) 2000-03-27
HUP0001964A3 (en) 2002-01-28
CA2278621A1 (en) 1998-07-30

Similar Documents

Publication Publication Date Title
NO993669D0 (no) Flersteds avlevering av adenoviral vektor for induksjon av angiogenese
WO2000021548A3 (en) Angiogenically effective unit dose of fgf and method of administering
DE60132343D1 (de) Fgf-2 zur behandlung von erkrankungen der peripheralen arterien
BR9206398A (pt) Peptídio, processo para promover a liberação de níveis de hormônio de crescimento em um animal, composição farmacêutica, processos para promover a liberação e elevação de níveis de hormônio de crescimento no sangue, para tratar nanismo pituitário hipotalâmico, osteoporose ou queimaduras, para promover a cicatrização de feridas, a recuperação de cirurgias ou recuperação de doenças debilitantes agudas/crônicas, para prevenir ou reduzir caquexia em pacientes com câncer, para promover o anabolismo e/ou evitar catabolismo em seres humanos, para aumentar o músculo em um animal e/ou diminuir a gordura do corpo, para melhorar o padrão de lipídios no soro em seres humanos, e para preparar compostos
ATE249238T1 (de) Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten
AP2003002761A0 (en) Methods of treatment of a BCL-2 disorder using BCL-2 antisense oligomers
IL135712A (en) Use of recombinant activated protein c in the manufacture of medicaments for treating or preventing acquired hypercoagulable states associated with sepsis
CA2233447A1 (en) Mimicking peptides in cancer therapy
HUT73465A (en) Adenoviral vectors of animal origin and use thereof in gene therapy
EP1005376A4 (en) METHODS AND COMPOSITIONS FOR USE IN GENE THERAPY FOR THE TREATMENT OF HEMOPHILIA
ATE419875T1 (de) Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha
FR2704556B1 (fr) Virus recombinants et leur utilisation en thérapie génique.
CA2473469A1 (en) Tolerogenic peptides from myelin basic protein
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
WO2000053219A3 (en) Compositions and methods for treating cancer and hyperproliferative disorders
EA200200533A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТОГО ЗАБОЛЕВАНИЯ ДОСТАВКОЙ ГЕНОВ in vivo
WO2002058720A3 (en) Angiogenically effective unit dose of fgf-2 and method of use
WO2000013701A3 (en) Angiogenically effective unit dose of fgf-2 and method of use
Webster Therapeutic angiogenesis: a case for targeted, regulated gene delivery
CA2394843A1 (en) A vaccine comprising lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias
ES2246156B1 (es) Uso de la anfiregulina como un agente protector en el daño hepatico agudo.
Massidda et al. Metastatic renal cell cancer treated with recombinant alpha 2a interferon and vinblastine
injection Histoacryl Spraying N-butyl-2-cyanoacrylate (Histoacryl) as a rescue therapy for gastrointestinal malignant tumor bleeding after failed conventional therapy
Ehsan et al. cycle regulatory genes56. Arrest of the cell cycle via antisense blockade of either of two